Visible science

Nicox develops innovative therapeutics to help maintain vision and improve ocular health
About us Our pipeline

Watch

Learn more about the mechanism of action of NCX 470, our lead product candidate in glaucoma

Latest news

  • Nicox Announces Publication of the Adaptive Design Period of the NCX 470 Mont Blanc Phase 3 Trial

    November 19, 2024 Read more

  • Nicox Provides Third Quarter 2024 update and First Half 2024 Financial Results

    October 17, 2024 Read more

  • Nicox and Soleus Sign $16.5 million Royalty and Equity Financing

    October 14, 2024 Read more
See all news

Cookies

By continuing to use this website, you agree to our Cookie Policy.